Summary of the “2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice”Article in several languages: deutsch | English
29 December 2017 (online)
Application of the “2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice” allows a precise and individualized cardiovascular risk estimation that can easily be employed in clinical practice. Preventive and therapeutic measures based on quantitative risk assessments (e.g. blood pressure, blood lipids, HbA1c, duration and intensity of weekly exercise) are well defined and mostly based on solid evidence from randomized trials and meta-analyses. This is not the case for most recommendations dealing with so-called life-style changes and population-based activities. With the exception of measures against smoking that have been proven to be efficacious, most other recommendations are vaguely defined and especially on the population level, merely represent not well validated expert opinions. It is this particular spectrum of recommendations that needs intensified attention in the future to increase their validity.
SchlüsselwörterKoronare Herzkrankheit - Adipositas - Cholesterin - Hypertonie - Diabetes mellitus - Bewegungsmangel - Rauchen - Prävention
- 1 Piepoli MF, Hoes A, Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovasular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J 2016; 37: 2315-2381.
- 2 ESC Pocket Guideline. European Society of Cardiology (ESC) und Deutsche Gesellschaft für Kardiologie (DGK). Prävention von Herz-KreislaufErkrankungen. 2016. Erhältlich unter. www.dgk. org
- 3 Kotseva K, Wood D, De Bacquer D. et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636-648.
- 4 Biffi A, Scotti L, Corrao G. Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies. Eur J Clin Pharmacol 2017; 73: 487-497.
- 5 Hambrecht R, Albus C, Halle M, Landmesser U, Löllgen H, Schuler GC, Perings S. Kommentar zu den neuen Leitlinien (2016) der Europäischen Gesellschaft für Kardiologie (ESC) zur kardiovaskulären Prävention. Kardiologe 2017; 11: 21-26.